SNPMiner Trials (Home Page)
Report for Mutation V140A
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study
In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of lung injury caused by COVID-19 can be an alternative target for current treatment. Patients with severe COVID-19 have rapid disease progression and high mortality. There is currently no effective treatment method, which may be related to the excessive immune response caused by cytokine storm. This study will evaluate thalidomide combined with low-dose hormone adjuvant therapy for severe COVID-19 Patient effectiveness and safety.
NCT04273581 COVID-19 Thalidomide Drug: placebo Drug: Thalidomide
There is currently no effective treatment method, which may be related to the excessive immune response caused by cytokine storm.It has been reported that the combined use of thalidomide and dexamethasone can effectively inhibit NK / T-cell lymphoma combined with ECSIT V140A mutation of hematophilic syndrome. --- V140A ---
Primary Outcomes
Description: TTCI is defined as the time (in days) from initiation of study treatment (active or placebo) until a decline of two categories from admission status on a six-category ordinal scale of clinical status which ranges from 1 (discharged) to 6 (death). Six-category ordinal scale: 6. Death; 5. ICU, requiring ECMO and/or IMV; 4. ICU/hospitalization, requiring NIV/ HFNC therapy; 3. Hospitalization, requiring supplemental oxygen (but not NIV/ HFNC); 2. Hospitalization, not requiring supplemental oxygen; 1. Hospital discharge. Abbreviation: IMV, invasive mechanical ventilation; NIV, non-invasive mechanical ventilation; HFNC, High-flow nasal cannula.
Measure: Time to Clinical Improvement (TTCI) Time: up to 28 daysSecondary Outcomes
Description: Clinical status, assessed by the ordinal scale at fixed time points
Measure: Clinical status Time: days 7, 14, 21, and 28Measure: Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours Time: up to 28 days
Measure: All cause mortality Time: up to 28 days
Measure: Duration (days) of mechanical ventilation Time: up to 28 days
Measure: Duration (days) of extracorporeal membrane oxygenation Time: up to 28 days
Measure: Duration (days) of supplemental oxygenation Time: up to 28 days
Measure: Length of hospital stay (days) Time: up to 28 days
Measure: Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens Time: up to 28 days
Measure: Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve. Time: up to 28 days
Measure: Frequency of serious adverse drug events Time: up to 28 days
Measure: Serum TNF-α, IL-1β, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1α and other cytokine expression levels before and after treatment Time: up to 28 days